Corona Remedies IPO
Alloted
Corona Remedies Limited is an India-focused branded pharmaceutical company specializing in developing and marketing products across high-growth chronic therapeutic areas, primarily women’s healthcare, cardio-diabeto, pain management, and urology. The company is recognized as the second-fastest-growing among the top 30 firms in the Indian Pharmaceutical Market (IPM) by domestic sales. It operates two manufacturing facilities in Gujarat and Himachal Pradesh and leverages a pan-India marketing network of 2,671 medical representatives.
Issue Price
1062
Current GMP
₹342 (32.20%)
Overall Subscription
144.49x
Issue Size
₹655.37 Cr
Advertisement
Live Subscription by Application
| Category | Applications Offered | Applications Received | Subscription |
|---|---|---|---|
| QIB | 12,21,729 | 6,584 | 0.01x |
FII | - | 144 | - |
DFI | - | 97 | - |
MF | - | 31 | - |
Other | - | 6,312 | - |
| NII | 4,678 | 4,05,165 | 86.61x |
bNII | 3,119 | 1,55,201 | 49.76x |
Corporate | - | 1,097 | - |
Individual | - | 1,45,362 | - |
Other | - | 8,742 | - |
sNII | 1,559 | 2,49,964 | 160.34x |
Corporate | - | 412 | - |
Individual | - | 2,37,973 | - |
Other | - | 11,579 | - |
| Retail | 1,52,827 | 37,91,888 | 24.81x |
Cut-off price | - | 31,15,556 | - |
Fixed price | - | 6,76,332 | - |
| Employee | 4,145 | 35,562 | 8.58x |
Cut-off price | - | 29,450 | - |
Fixed price | - | 6,112 | - |
| Total | 13,83,379 | 42,39,199 | 3.06x |
Live Subscription by Shares
| Category | Shares Offered | Shares Applied | Subscription |
|---|---|---|---|
| QIB | 12.22 L | 35.89 Cr | 293.80x |
FII | - | 8.73 Cr | - |
DFI | - | 15.58 Cr | - |
MF | - | 2.20 Cr | - |
Other | - | 9.39 Cr | - |
| NII | 9.17 L | 20.19 Cr | 220.18x |
bNII | 6.11 L | 15.08 Cr | 246.67x |
Corporate | - | 12.63 L | - |
Individual | - | 14.11 Cr | - |
Other | - | 83.97 L | - |
sNII | 3.06 L | 5.11 Cr | 167.20x |
Corporate | - | 94.37K | - |
Individual | - | 4.87 Cr | - |
Other | - | 23.14 L | - |
| Retail | 21.40 L | 6.48 Cr | 30.29x |
Cut-off price | - | 5.38 Cr | - |
Fixed price | - | 1.10 Cr | - |
| Employee | 58.04K | 9.03 L | 15.56x |
Cut-off price | - | 7.17 L | - |
Fixed price | - | 1.86 L | - |
| Total | 43.36 L | 62.65 Cr | 144.49x |
Subscription Summary
QIB
Shares Applied:293.80x
Applications Offered:0.01x
NII
Shares Applied:220.18x
Applications Offered:86.61x
Retail
Shares Applied:30.29x
Applications Offered:24.81x
Employee
Shares Applied:15.56x
Applications Offered:8.58x
Quick Stats
Total Categories4
IPO TypeMainboard
StatusAllotment Out
Join us on Telegram for instant IPO updates!
Join NowData Last Updated
11 Dec 2025, 01:22 pm
Auto-refreshing
Advertisement
Understanding Subscription Categories
QIB
Qualified Institutional Buyers
Includes FII, DFI, Mutual Funds, and other qualified institutions.
NII
Non-Institutional Investors
High net-worth individuals: bNII (₹10L+) and sNII (₹2L-₹10L).
Retail
Retail Individual Investors
Retail investors with applications up to ₹2 lakh per PAN.
Frequently Asked Questions
What is the current subscription status of Corona Remedies IPO?
The current overall subscription for Corona Remedies IPO is 144.49x. This indicates the total demand relative to the shares offered. Higher subscription typically suggests strong investor interest.
How to check Corona Remedies IPO subscription status?
You can check Corona Remedies IPO subscription status on IPOwiz, BSE website, NSE website, or your broker's platform. Subscription data is updated regularly during the IPO period from 8 December 2025 to 10 December 2025.
What do subscription numbers mean?
Subscription numbers show how many times the IPO is oversubscribed. For example, 144.49x means the IPO received 144.49x times more applications than shares available. Higher subscription in retail category generally means lower allotment chances.
When does Corona Remedies IPO subscription close?
The subscription for Corona Remedies IPO closes on 10 December 2025. Applications must be submitted before the closing time on this date. Late applications will not be accepted.
What is the difference between QIB, NII, and Retail subscription?
QIB (Qualified Institutional Buyers) includes mutual funds, FIIs, and other institutions. NII (Non-Institutional Investors) includes high net-worth individuals investing above ₹2 lakh. Retail includes individual investors with applications up to ₹2 lakh. Each category has separate subscription quotas.
How does subscription affect allotment chances?
Higher subscription in your category means lower allotment chances. For example, if retail subscription is 144.49x, it means there are 144.49x times more applications than shares available, making allotment competitive.
When will Corona Remedies IPO allotment be finalized?
The allotment for Corona Remedies IPO will be finalized and announced on 11 December 2025. You can check your allotment status on the registrar's website, BSE, NSE, or your demat account after this date.
What happens after subscription closes?
After subscription closes on 10 December 2025, the company and registrar process all applications. Allotment is finalized by 11 December 2025, and shares are credited to successful applicants' demat accounts before the listing date on 15 December 2025.
Can I apply after subscription closes?
No, you cannot apply after the subscription closes on 10 December 2025. All IPO applications must be submitted during the subscription period from 8 December 2025 to 10 December 2025. Late applications are automatically rejected.
What is the issue size and lot size for Corona Remedies IPO?
The issue size for Corona Remedies IPO is ₹655.37 Cr, and the lot size is 14 shares. The price range is ₹1008.0 - ₹1062.0. You must apply in multiples of the lot size.